Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCGX9Y)

Drug Name

SNDX-5613 Drug Info

Synonyms

2169919-21-3; SNDX5613; SCHEMBL19693219; SCHEMBL19693428; EX-A4343; NSC825775; NSC-825775; HY-136175; CS-0120274

Indication

Disease Entry	ICD 11	Status	REF
T lymphoblastic leukaemia	2B33.4	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Menin-MLL1 interaction (MEN1-KMT2A PPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KO-539	DM0NZYC	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
JNJ-75276617	DMR5RHG	Haematological malignancy	2B33.Y	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Menin-MLL1 interaction (MEN1-KMT2A PPI)	TT0CZBQ	MEN1_HUMAN-KMT2A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04065399) A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Syndax Pharmaceuticals.
3	Clinical pipeline report, company report or official report of Kura Oncology.
4	Targeting the undruggable: menin inhibitors ante portas. J Cancer Res Clin Oncol. 2023 Sep;149(11):9451-9459.